<?xml version="1.0" encoding="UTF-8"?>
<ref id="B91-vaccines-08-00038">
 <label>91.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Anywaine</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Whitworth</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Kaleebu</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Praygod</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Shukarev</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Manno</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Kapiga</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Grosskurth</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Kalluvya</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bockstal</surname>
    <given-names>V.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and Immunogenicity of a 2-dose Heterologous Vaccination Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a Phase 1 Randomized Clinical Trial in Uganda and Tanzania</article-title>
  <source>J. Infect. Dis.</source>
  <year>2019</year>
  <volume>220</volume>
  <fpage>46</fpage>
  <lpage>56</lpage>
  <comment>Available online: 
   <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548900/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548900/</ext-link>
  </comment>
  <date-in-citation content-type="access-date" iso-8601-date="2020-01-01">(accessed on 1 January 2020)</date-in-citation>
  <pub-id pub-id-type="doi">10.1093/infdis/jiz070</pub-id>
  <pub-id pub-id-type="pmid">30796818</pub-id>
 </element-citation>
</ref>
